The power of healthcare data gives rise to novel markers of cardiovascular disease and stroke in the earliest, preventable stages CHICAGO, Nov.11, 2018 — Developing novel approaches to understand cardiovascular health and pre-disease is the cornerstone strategy of One Brave Idea™, a research initiative led by Dr. Calum MacRae, vice chair for Scientific Innovation in the department of Medicine at Brigham …
Cleveland HeartLab and Quest Diagnostics Forming Base for Quest’s National Cardiometabolic Center of Excellence
– Cleveland HeartLab to be the base for Quest’s first national center of excellence in cardiometabolic disorders, with a focus on services that help patients and physicians nationwide identify hidden risks of heart disease – Relationship to establish a strategic collaboration to identify and offer diagnostic services from Cleveland Clinic’s innovations in inflammation and other areas of medicine SECAUCUS, N.J. and …
Cleveland HeartLab Launches Only Clinical Test for Measuring TMAO, an Important Measure of Gut Dysfunction that is Associated with Cardiovascular Disease Risk
Download Press Release Innovative new test published in The New England Journal of Medicine detects levels of TMAO – which, when elevated, correlates with a two-fold increased risk of heart attack or stroke February 16, 2016, CLEVELAND: Cleveland HeartLab Inc., the premier cardiovascular disease management company, announced it has successfully developed, validated and launched a new clinical test for the assessment of …
Cleveland HeartLab Partnering with Procter & Gamble and Cleveland Clinic to Advance Discovery in Heart Disease with TMAO Testing
Link to Press Release Corporate Communications 9500 Euclid Ave. / JJN4-01 Cleveland, OH 44195 Phone: 216.444.0141 Fax: 216.445.3040 clevelandclinic.org/newsroom Contacts: Cleveland Clinic: Robert Smith, 216.385.6179, smithr5@ccf.org P&G: Michelle Vaeth, 513-622-4727, vaeth.m@pg.com Cleveland HeartLab: Bethany Hilt, 330-338-6633, bethany.hilt@gmail.com CLEVELAND CLINIC PARTNERING WITH PROCTER & GAMBLE AND CLEVELAND HEARTLAB TO ADVANCE DISCOVERY IN HEART DISEASE The Partners Will Build Upon …
Journal of Medical Economics – CHL testing could reduce events by 10%, saving $187 Million
Link to Press Release New Study Shows Cleveland HeartLab Inflammation Testing can Prevent Thousands of Heart Attacks and Strokes, Averting $187 Million in Healthcare Costs for Cardiovascular Disease—The Number One Killer of Men and Women in the U.S The American Heart Association estimates 50 percent of all heart attacks and strokes occur in individuals with normal cholesterol. Cleveland HeartLab’s inflammation …
Nutrasource Diagnostics Inc. Announces the Availability of the OmegaCheck™ Omega-3 Blood Test through Cleveland HeartLab
Link to PRWeb Press Release Guelph, Ontario, Canada (February 23, 2015) Nutrasource Diagnostics Inc. (NDI) is pleased to announce its recent collaboration with Cleveland HeartLab (CHL) for the development of the OmegaCheck™ diagnostic blood test for the quantification of omega fatty acids. As a global leader in launching proprietary tests to more accurately assess cardiovascular disease risk, CHL developed and …
CHL Launches New Medical Education Program
Link to PRWeb Press Release World-class, accredited continuing medical education (CME) now available as one-stop source for information on the identification and prevention of metabolic and cardiovascular disease CLEVELAND, March 9, 2015 – Cleveland HeartLab (CHL), the premier cardiovascular management company, announces the launch of its new CME Web Portal, Continuing Education from Cleveland HeartLab. The website (www.chlcme.com ) will …
Cleveland HeartLab Tests can save $180 Million in Healthcare Costs, As discussed on Yahoo Health:
Cleveland HeartLab Presents Research Demonstrating its Prognostic Tests can save $180 Million in Healthcare costs related to Cardiovascular Disease, the Number One killer of Men and Women in the US Read the Story on Yahoo Health: http://health.yahoo.net/experts/dayinhealth/simple-tests-heart-attack-risk-could-save-lives-and-180-million First-of-its-kind economic model to be presented today at the International Society of PharmacoEconomics and Outcomes Research (ISPOR) conference validates enormous cost savings from …
Clinical Experts and Entrepreneurs to Converge on Cleveland to Discuss Broad-Based Strategies for Reducing Chronic Disease
Cleveland HeartLab announces highlight speakers for its Fifth Annual Symposium, “Where Inflammation Meets Lipids®: Broad-Based Strategies for Chronic Disease Prevention.” CLEVELAND, February 25, 2014 – Cleveland HeartLab Inc., a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today announced that its Fifth Annual Symposium titled, “Where Inflammation Meets Lipids®: Broad-Based Strategies for Chronic Disease Prevention,” will focus on …
Inflammation Testing Proving Valuable Predictor of Cardiac Risk for Corporate Wellness Programs
Cleveland HeartLab CEO to present findings at Health & Wellness Congress CLEVELAND, OH (Feb. 5, 2014) – Leading companies are increasingly recognizing that traditional fingerstick screening for glucose and lipids is proving inadequate when identifying near-term cardiovascular risk in employed populations, according to Jake Orville, CEO of Cleveland HeartLab (CHL). This position is supported by data from the American Heart …
Fine-Tuning the Investment in Employee Health
CLEVELAND – August 2013 – When Classic Auto Group launched its car shopping website, they said they were bringing the showroom direct to the customer. This month, Classic Auto Group is launching a new employee health program based on the same principle: bringing health care directly to their employees. Despite spending over $100,000 on the program, president Jim Brown knows from experience that it won’t …
Report Confirms Multimarker Approach as Definitive Tool
Report Confirms Multimarker Approach as Definitive Tool to Identify and Help Diminish Cardiovascular Risk –Cleveland HeartLab and MDVIP Co-Authored, Peer-Reviewed Article Analyzing Biomarker Test Data from 95,000 Patients– (July 18, 2013, Boca Raton, FL & Cleveland, OH) – A just-published report, co-authored by the medical leadership of Cleveland HeartLab (CHL) and MDVIP for the peer-reviewed journal Future Cardiology (July 2013), clearly …
Oswald Companies Announces Partnership with Cleveland HeartLab
Oswald Companies, one of the largest independently owned insurance brokerage and consulting firms in the U.S., is proud to offer its clients the next generation of health screenings through a strategic partnership with Cleveland HeartLab, Inc.
Cleveland HeartLab announces speakers for its 4th annual symposium
Cleveland HeartLab announces speakers for its 4th annual symposium on cardiovascular disease, preventive medicine 12 CME credits approved for this industry-leading event CLEVELAND, Aug. 28, 2013 – Cleveland HeartLab Inc. (CHL), a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today announced that its fourth annual symposium, Where Inflammation Meets Lipids®, will focus on unique models and strategies for …
CHL Honored with Prestigious 2013 NorTech Innovation Award
CLEVELAND, March 15, 2013 – Cleveland HeartLab announced today that the company was recognized as a recipient of the 2013 NorTech Innovation Awards. The award was received yesterday by Cleveland HeartLab, President and CEO, Jake Orville at the annual awards ceremony in Independence, Ohio. Cleveland HeartLab was recognized for its work in the field of applied biosciences for leadership in …
Cleveland HeartLab announces $14.7 million financing
Contacts: Jake Orville President & Chief Executive, Cleveland HeartLab Inc. 216-426-6081 Jason Lansdale Marketing Manager, Cleveland HeartLab Inc. 216-426-6081, ext. 1450 Rod Hise The Luminis Group, Ltd. for Cleveland HeartLab Inc. 608-770-7850 For Immediate Release Cleveland HeartLab closes $14.7-million financing CLEVELAND, Oct. 22, 2012 – Cleveland HeartLab Inc. (CHL), a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today …
Cleveland HeartLab New Leadership 2012
Contacts: Jake Orville President & Chief Executive, Cleveland HeartLab Inc. 216-426-6081 Jason Lansdale Marketing Manager, Cleveland HeartLab Inc. 216-426-6081, ext. 1450 Rod Hise The Luminis Group, Ltd. for Cleveland HeartLab Inc. 608-770-7850 For Immediate Release Cleveland HeartLab expands scientific, sales leadership teams with appointment of three key executives CLEVELAND, Aug. 7, 2012 – Cleveland HeartLab Inc. (CHL), a rapidly growing …
CHL Launches “it” inflammation testing Campaign
Cleveland HeartLab Launches “it” Campaign to Raise Awareness of Inflammation Testing April 11, 2012 09:03 AM Eastern Daylight Time CLEVELAND — Cleveland HeartLab Inc. (CHL), a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today announced the launch of a campaign to educate patients and health care professionals about the importance of “it,” or inflammation testing, in determining …